World's Best Scientists 2026 revealed!
Suzanne Kamel-Reid

Suzanne Kamel-Reid

D-Index & Metrics

Medicine

D-Index
75
Citations
21857
World Ranking
19095
National Ranking
810

Suzanne Kamel-Reid publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Suzanne Kamel-Reid sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 397 publications — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Suzanne Kamel-Reid D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Suzanne Kamel-Reid sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 75 D-Index — 6th percentile

6% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Suzanne Kamel-Reid is affiliated with the University Health Network in Canada. Their research primarily focuses on Medicine, with significant contributions to subfields such as Hematology, Pulmonary and Respiratory Medicine, Genetics, Oncology, and Cancer Research.

Their recent scholarly output includes research on chronic myeloid leukemia treatments, lung cancer treatments and mutations, and various aspects of cancer genomics and diagnostics. Their main topics of work also cover colorectal cancer treatments and studies, chronic lymphocytic leukemia research, ovarian cancer diagnosis and treatment, as well as eosinophilic disorders and syndromes.

Collaborations have been a part of their research activities, with frequent co-authors including Tracy Stockley, Eshetu G. Atenafu, Tong Zhang, Ming-Sound Tsao, and Dennis Dong Hwan Kim.

The most common venues where Suzanne Kamel-Reid has published include Scientific Reports, British Journal of Haematology, Blood, Haematologica, and Clinical Cancer Research.

Notable recent papers include:

  • Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia, 2020, Haematologica
  • Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86), 2020, Clinical Cancer Research
  • A 4-gene signature from histologically normal surgical margins predicts local recurrence in patients with oral carcinoma: clinical validation, 2020, Scientific Reports
  • Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial, 2021, British Journal of Haematology
  • Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories, 2020, JCO Precision Oncology

Best Publications

  • Erlotinib in lung cancer - molecular and clinical predictors of outcome.

    Ming Sound Tsao;Akira Sakurada;Jean Claude Cutz;Jean Claude Cutz;Chang Qi Zhu;Chang Qi Zhu

  • Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

    Timothy P Hughes;Michael W Deininger;Andreas Hochhaus;Susan Branford

  • Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

    Chang Qi Zhu;Gilda Da Cunha Santos;Keyue Ding;Akira Sakurada

  • Engraftment of immune-deficient mice with human hematopoietic stem cells

    Suzanne Kamel-Reid;John E. Dick

  • Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.

    Lawrence J. Jennings;Maria E. Arcila;Christopher Corless;Suzanne Kamel-Reid;Suzanne Kamel-Reid

  • Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

    Susan Branford;Linda Fletcher;Nicholas C.P. Cross;Martin C. Müller

  • Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

    Amit M. Oza;Laurie Elit;Ming-Sound Tsao;Suzanne Kamel-Reid

  • Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia.

    Richard A. Wells;Charles Catzavelos;Suzanne Kamel-Reid;Suzanne Kamel-Reid

  • A model of human acute lymphoblastic leukemia in immune-deficient SCID mice

    Suzanne Kamel-Reid;Michelle Letarte;Christian Sirard;Monica Doedens

  • Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma

    Nilva K. Cervigne;Patricia P. Reis;Jerry Machado;Bekim Sadikovic

  • mRNA transcript quantification in archival samples using multiplexed, color-coded probes

    Patricia P Reis;Levi Waldron;Rashmi S Goswami;Rashmi S Goswami;Wei Xu

  • A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

    Brian Thiessen;Clinton Stewart;Ming Tsao;Suzanne Kamel-Reid

  • Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.

    Tracy L. Stockley;Tracy L. Stockley;Tracy L. Stockley;Amit M. Oza;Amit M. Oza;Hal K. Berman;Hal K. Berman;Natasha B. Leighl;Natasha B. Leighl

  • Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer

    C. Lim;M.S. Tsao;L.W. Le;F.A. Shepherd

  • Cancer Genomics: Technology, Discovery, and Translation

    Ben Tran;Janet E. Dancey;Suzanne Kamel-Reid;John Douglas Mcpherson;John Douglas Mcpherson

  • A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.

    Aaron D. Schimmer;Susan O'Brien;Hagop Kantarjian;Joseph Brandwein

  • Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia

    Dong Hwan Dennis Kim;Lakshmi Sriharsha;Wei Xu;Suzanne Kamel-Reid

  • A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

    Jerald P. Radich;Kenneth J. Kopecky;Frederick R. Appelbaum;Suzanne Kamel-Reid

  • Biomarker testing and time-to-treatment decision in patients with advanced non-small cell lung cancer.

    Charles Henry Lim;Lisa Le;Frances A. Shepherd;Ronald Feld

  • Additional file 1: of Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

    Tracy Stockley;Amit Oza;Hal Berman;Natasha Leighl

Frequent Co-Authors

Ming-Sound Tsao
Ming-Sound Tsao Princess Margaret Cancer Centre
Vikas Gupta
Vikas Gupta Princess Margaret Cancer Centre
Natasha B. Leighl
Natasha B. Leighl Princess Margaret Cancer Centre
Mark D. Minden
Mark D. Minden Princess Margaret Cancer Centre
Frances A. Shepherd
Frances A. Shepherd Princess Margaret Cancer Centre
Lillian L. Siu
Lillian L. Siu University of Toronto
Aaron D. Schimmer
Aaron D. Schimmer Princess Margaret Cancer Centre
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Geoffrey Liu
Geoffrey Liu Princess Margaret Cancer Centre
Melania Pintilie
Melania Pintilie Princess Margaret Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Medicine but seeking alternative or complementary healthcare careers, online degrees can offer flexible and affordable options. Nursing remains one of the most popular paths, with programs designed to fit a range of student backgrounds and career goals.

Aspiring nurses or those seeking to advance their credentials can explore some of the cheapest online msn programs available, allowing graduates to move into advanced practice or leadership roles. For those wishing to reach the highest academic level in the field, there are also cheapest phd nursing programs, which prepare students for careers in research, education, or clinical leadership.

Registered Nurses (RNs) looking to complete their bachelor’s degree can benefit from a variety of affordable rn to bsn programs designed for working professionals. Meanwhile, individuals with a non-nursing bachelor’s degree who wish to enter the nursing field quickly can consider direct entry nurse practitioner programs for non-nurses online.

Exploring these online degree options can open new doors for those seeking rewarding careers in healthcare, both within and alongside the field of Medicine in the USA.

Best Scientists Citing Suzanne Kamel-Reid

Trending Scientists

Recently Published Articles